Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASC41 in Overweight and Obese Subjects
NCT04686994Phase 1Completed
- Sponsor
- Gannex Pharma Co., Ltd.
- Start
- Dec 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hyperlipidemia and non-alcoholic fatty liver disease (NAFLD) comparing ASC41 with Placebo (2 arms). Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 28 days. Started Dec 2020; status: completed.
02
Drugs
ASC-41
03
Conditions
hyperlipidemianon-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT04686994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04686994.